GlobeNewswire Inc.··NaBioCryst Lands $70M European Deal for Hereditary Angioedema Drug
BioCryst secures $70M upfront plus $275M milestone payments for navenibart European rights, reinforcing strategy to focus on U.S. commercialization.
BCRXPhase 3 clinical trialORLADEYO